J. Safra Sarasin Holding AG Sells 6,078 Shares of Danaher Corporation $DHR

Key Points

• J. Safra Sarasin Holding AG decreased its stake in Danaher Corporation (NYSE:DHR) by 5.4%, selling 6,078 shares, leaving them with 105,975 shares valued at approximately $20.9 million.
• A range of institutional investors made changes to their positions in Danaher, demonstrating significant interest in the stock, which is primarily owned by institutional investors at 79.05%.
• Wall Street analysts have a consensus rating of "Moderate Buy" for Danaher, with a price target averaging $245.91, indicating potential growth and positive sentiment in the market.

J. Safra Sarasin Holding AG reduced its stake in Danaher Corporation (NYSE:DHR - Free Report) by 5.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 105,975 shares of the conglomerate's stock after selling 6,078 shares during the period. J. Safra Sarasin Holding AG's holdings in Danaher were worth $20,934,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in DHR. NBC Securities Inc. acquired a new stake in Danaher in the first quarter valued at approximately $176,000. Merit Financial Group LLC lifted its holdings in shares of Danaher by 44.8% in the 1st quarter. Merit Financial Group LLC now owns 14,555 shares of the conglomerate's stock worth $2,984,000 after purchasing an additional 4,505 shares in the last quarter. Lmcg Investments LLC grew its position in Danaher by 11.0% in the 1st quarter. Lmcg Investments LLC now owns 103,988 shares of the conglomerate's stock valued at $21,318,000 after purchasing an additional 10,342 shares during the period. Thurston Springer Miller Herd & Titak Inc. increased its stake in Danaher by 26.9% during the 1st quarter. Thurston Springer Miller Herd & Titak Inc. now owns 5,914 shares of the conglomerate's stock valued at $1,212,000 after purchasing an additional 1,252 shares in the last quarter. Finally, Thrive Wealth Management LLC increased its stake in Danaher by 16.4% during the 1st quarter. Thrive Wealth Management LLC now owns 6,710 shares of the conglomerate's stock valued at $1,376,000 after purchasing an additional 945 shares in the last quarter. Institutional investors own 79.05% of the company's stock.

Insider Activity

In related news, Director Teri List sold 2,778 shares of the business's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 11.10% of the company's stock.

Wall Street Analysts Forecast Growth

DHR has been the subject of several recent research reports. Barclays reissued an "overweight" rating and set a $225.00 target price (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Robert W. Baird increased their price objective on Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research note on Friday, July 18th. Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price on the stock in a report on Friday, July 11th. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Finally, Evercore ISI dropped their price objective on Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $245.91.

Danaher Stock Performance

Shares of DHR opened at $210.64 on Friday. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.41. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The stock's fifty day moving average price is $200.00 and its two-hundred day moving average price is $197.40. The firm has a market cap of $150.83 billion, a PE ratio of 44.82, a PEG ratio of 3.03 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same quarter last year, the firm posted $1.72 EPS. The firm's revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities research analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's dividend payout ratio (DPR) is presently 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.